YMAB Stock: Y-mAbs Therapeutics, Inc. Stock Price, Analysis & Insights

Get live YMAB stock price $8.61, comprehensive Y-mAbs Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time YMAB stock data and investment insights.

Quick links:Financial Metrics•Earnings•Analyst Forecasts•Financials•Technicals

8.61

0.23%Today

YMAB • Y-mAbs Therapeutics, Inc. • NASDAQ Global Select • Healthcare

Market Cap

391.22M

Volume

760.67K

52W High

16.11

52W Low

3.55

Loading chart data...

Investment Score

Annual (latest period)

Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

View full dashboardUnlock quarterlyFaster signals · Pro+

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Y-mAbs Therapeutics, Inc. is a biopharmaceutical firm already generating revenue, dedicated to discovering, advancing, and selling innovative antibody-derived therapies specifically designed to combat cancer within the United States. Its flagship pro...

Contact Information

Website: https://www.ymabs.com
Address: 230 Park Avenue
Country: US

Investment Analysis & Business Insights

Healthcare

Biotechnology

Investment Highlights

✓ Strong presence in the Healthcare sector with established market position

✓ Lower volatility stock (Beta: 0.53) may provide portfolio stability

Important Investment Considerations

⚠All investments carry risk, including potential loss of principal for Y-mAbs Therapeutics, Inc. shareholders
⚠Market volatility can significantly impact stock price, especially for smaller companies
⚠Sector-specific risks in Healthcare may affect company performance
⚠Past performance does not guarantee future results for Y-mAbs Therapeutics, Inc.
⚠Investors should consider how Y-mAbs Therapeutics, Inc. fits within their overall portfolio allocation
⚠Valuation metrics suggest potential, but require fundamental analysis

Market Cap

391.22M

P/E Ratio (TTM)

-17.22

Beta

0.53

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

Related Stocks

Compare YMAB with peer companies:

Big Cypress Acquisition Corp. (BCYP)

Price: $8.44
Market cap: 425.36M

Checkpoint Therapeutics, Inc. (CKPT)

Price: $4.26
Market cap: 367.72M

Climb Bio, Inc. (CLYM)

Price: $10.80
Market cap: 736.39M

G1 Therapeutics, Inc. (GTHX)

Price: $7.16
Market cap: 377.75M

iTeos Therapeutics, Inc. (ITOS)

Price: $10.15
Market cap: 448.68M

Orchard Therapeutics plc (ORTX)

Price: $16.70
Market cap: 380.11M

Revance Therapeutics, Inc. (RVNC)

Price: $3.65
Market cap: 381.02M

SomaLogic, Inc. (SLGC)

Price: $2.10
Market cap: 396.23M

Sinovac Biotech Ltd. (SVA)

Price: $6.47
Market cap: 464.94M

Vigil Neuroscience, Inc. (VIGL)

Price: $8.05
Market cap: 375.71M

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.